- Home
- TIL vs VGI Comparison
TIL vs VGI Comparison
Compare TIL & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- VGI
- Stock Information
- Founded
- TIL 2018
- VGI 2012
- Country
- TIL United States
- VGI United States
- Employees
- TIL N/A
- VGI N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- VGI Investment Managers
- Sector
- TIL Health Care
- VGI Finance
- Exchange
- TIL Nasdaq
- VGI Nasdaq
- Market Cap
- TIL 230.1M
- VGI N/A
- IPO Year
- TIL 2021
- VGI N/A
- Fundamental
- Price
- TIL $28.30
- VGI $7.92
- Analyst Decision
- TIL Buy
- VGI
- Analyst Count
- TIL 5
- VGI 0
- Target Price
- TIL $119.00
- VGI N/A
- AVG Volume (30 Days)
- TIL 349.6K
- VGI 46.0K
- Earning Date
- TIL 08-12-2025
- VGI 01-01-0001
- Dividend Yield
- TIL N/A
- VGI 12.66%
- EPS Growth
- TIL N/A
- VGI N/A
- EPS
- TIL N/A
- VGI N/A
- Revenue
- TIL N/A
- VGI N/A
- Revenue This Year
- TIL N/A
- VGI N/A
- Revenue Next Year
- TIL N/A
- VGI N/A
- P/E Ratio
- TIL N/A
- VGI N/A
- Revenue Growth
- TIL N/A
- VGI N/A
- 52 Week Low
- TIL $9.62
- VGI $6.68
- 52 Week High
- TIL $92.00
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- TIL 46.80
- VGI 69.29
- Support Level
- TIL $20.60
- VGI $7.50
- Resistance Level
- TIL $25.95
- VGI $7.73
- Average True Range (ATR)
- TIL 3.47
- VGI 0.07
- MACD
- TIL -1.29
- VGI 0.02
- Stochastic Oscillator
- TIL 22.74
- VGI 89.36
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.